摘要
Abstract
Objective:To investigate the effect of combined use of Levosimendan and Dobutamine in the treatment of patients with acute heart failure(AHF).Method:A total of 82 patients with AHF who admitted to Putian University Affiliated Hospital from January 2022 to July 2023 were selected as the study objects,and they were randomly divided into the conventional group(n=41)and the treatment group(n=41)using a random number table method.The conventional group was treated with Dobutamine,and in addition to the conventional group,the treatment group was treated with Levosimendan.The clinical efficacy,cardiac function[stroke output(SV),left ventricular ejection fraction(LVEF),cardiac index(CI)],inflammatory response[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and adverse reactions between two groups were compared.Result:Compared with the conventional group,the total effective rate of the treatment group was higher,and the difference was statistically significant(P<0.05);compared with before treatment,the SV,LVEF and CI in two groups after treatment were higher,and the above indicators in the treatment group were higher than those in the conventional group,the differences were statistically significant(P<0.05);compared with before treatment,the levels of serum hs-CRP,IL-6 and TNF-α in two groups after treatment decreased,and the above indicators in the treatment group were lower than those in the control group,the differences were statistically significant(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Levosimendan combined with Dobutamine in the treatment of AHF is effective,it can reduce inflammatory reactions,improve cardiac function,and has good safety.关键词
急性心力衰竭/左西孟旦/多巴酚丁胺/心功能Key words
Acute heart failure/Levosimendan/Dobutamine/Cardiac function
